Stem Cells and COVID-19 presents up-to-date knowledge on the effect of hematopoietic and mesenchymal stem cells to combat SARS-CoV-2 infection in its diagnosis, treatment and prevention. In addition, the book critically discusses challenges, highlighting outstanding questions and future perspectives. Written by global experts in the field for both pre-clinical and clinical practitioners, this comprehensive book delves into how stem cells have a strong potential in developing better diagnostic, treatment and preventive strategies in SARS-CoV-2 infection.
Both hematopoietic and mesenchymal stem cells are critical to better understand the response of immune system to coronavirus infection in both healthy and co-morbid conditions in the development of effective vaccines and immunotherapies.
- Focuses on diagnosis, treatment and prevention
- Presents different aspects to enable researchers in the field to move toward designing novel therapeutics in the treatment of COVID-19
- Provides coverage of challenges and future perspectives in this fast-moving field
| Contributors |
|
xi | |
| Preface |
|
xiii | |
|
|
|
1 | (6) |
|
|
|
|
|
|
|
Chapter 2 Characteristics and immunobiology of COVID-19 |
|
|
7 | (16) |
|
|
|
|
|
|
|
|
|
|
|
7 | (1) |
|
|
|
8 | (1) |
|
|
|
9 | (3) |
|
Immunology and signaling mechanisms |
|
|
12 | (2) |
|
|
|
14 | (2) |
|
Current treatment approaches |
|
|
16 | (1) |
|
Translational avenues and perspectives |
|
|
17 | (1) |
|
|
|
17 | (1) |
|
|
|
18 | (1) |
|
|
|
18 | (5) |
|
Chapter 3 An insight into the molecular mechanisms of mesenchymal stem cells and their translational approaches to combat COVID-19 |
|
|
23 | (24) |
|
|
|
|
|
|
|
Introduction and background |
|
|
23 | (2) |
|
Pathophysiology of SARS-CoV-2 |
|
|
25 | (1) |
|
Conventional and contemporary translational approaches to combat COVID-19 |
|
|
26 | (4) |
|
Stem cell therapy as a novel translation approach against the COVID-19 pandemic |
|
|
30 | (10) |
|
Conclusion and outlook for the future |
|
|
40 | (1) |
|
|
|
41 | (1) |
|
|
|
41 | (1) |
|
|
|
41 | (1) |
|
|
|
41 | (6) |
|
Chapter 4 Inflammatory multisystem syndrome in COVID-19: Insights on off-target organ system in susceptible and recovering population |
|
|
47 | (12) |
|
|
|
|
|
47 | (1) |
|
Antigen processing and immune responses in COVID-19 |
|
|
48 | (1) |
|
|
|
49 | (1) |
|
|
|
50 | (1) |
|
Respiratory system failure |
|
|
50 | (1) |
|
Cardiovascular manifestations in COVID-19 |
|
|
51 | (1) |
|
Neurological and renal manifestation of COVID-19 |
|
|
52 | (1) |
|
|
|
53 | (1) |
|
|
|
54 | (1) |
|
|
|
55 | (1) |
|
|
|
55 | (4) |
|
Chapter 5 Cytokine storm and stem cell activation in unveiling potential targets for diagnosis and therapy |
|
|
59 | (12) |
|
|
|
|
|
|
|
59 | (1) |
|
|
|
59 | (1) |
|
Cytokine storms in viral respiratory infections |
|
|
60 | (3) |
|
Cytokine storms and stem cells |
|
|
63 | (2) |
|
|
|
65 | (2) |
|
|
|
67 | (1) |
|
|
|
67 | (4) |
|
Chapter 6 Mesenchymal stem cells: Novel avenues in combating COVID-19 |
|
|
71 | (24) |
|
|
|
|
|
|
|
71 | (2) |
|
Alveolar cell and SARS-COVID-19 |
|
|
73 | (2) |
|
|
|
75 | (3) |
|
The reason behind using mesenchymal stem cells |
|
|
78 | (11) |
|
|
|
89 | (1) |
|
|
|
89 | (6) |
|
Chapter 7 Immunomodulatory properties of mesenchymal stem cells and hematopoietic stem cells---Potential therapeutic target for COVID-19 |
|
|
95 | (16) |
|
|
|
|
|
|
|
95 | (3) |
|
MSC as a cellular therapy |
|
|
98 | (4) |
|
|
|
102 | (1) |
|
Translational potential of MSCs |
|
|
103 | (1) |
|
|
|
104 | (1) |
|
|
|
105 | (1) |
|
|
|
105 | (6) |
|
Chapter 8 COVID-19 and acute myocardial injury: Stem cell driven tissue remodeling in COVID-19 infection |
|
|
111 | (14) |
|
|
|
Mereena George Ushakumary |
|
|
|
|
|
|
|
|
111 | (1) |
|
COVID-19: Etiology, transmission, structure, and pathophysiology |
|
|
112 | (1) |
|
|
|
113 | (1) |
|
Stem cells in cardiac remodeling |
|
|
114 | (1) |
|
ACE2 signaling and cardiac pathology COVID-19 infection |
|
|
115 | (2) |
|
Stem cell activation and signaling in ACE2 upregulation |
|
|
117 | (1) |
|
Cytokine surge and stem cell activation in MI |
|
|
117 | (1) |
|
Sheddases' response in cardiac stem cell differentiation (major focus to TMPRSS2, CTSL, and ADAM17) |
|
|
118 | (1) |
|
Perspectives in COVID-19 and cardiac responses |
|
|
119 | (1) |
|
Translational avenues and future |
|
|
120 | (1) |
|
|
|
121 | (4) |
|
Chapter 9 Stem cell-driven tissue regeneration as treatment for COVID-19 |
|
|
125 | (14) |
|
|
|
|
|
Mereena George Ushakumary |
|
|
|
|
125 | (1) |
|
Management of COVID-19 by stem cells |
|
|
125 | (2) |
|
Stem cell activation during pathology |
|
|
127 | (1) |
|
Growth factors as a vital target |
|
|
128 | (1) |
|
|
|
129 | (2) |
|
|
|
131 | (1) |
|
|
|
132 | (7) |
|
Chapter 10 Stem cell transplantation for COVID-19 management: Translational possibilities and future |
|
|
139 | (14) |
|
|
|
|
|
|
|
|
|
139 | (1) |
|
|
|
140 | (1) |
|
Use of different types of stem cells in translational research |
|
|
141 | (1) |
|
Current COVID-19 related clinical trials using stem cells |
|
|
142 | (2) |
|
Challenges of using stem cells and future perspective |
|
|
144 | (5) |
|
|
|
149 | (1) |
|
|
|
149 | (4) |
|
Chapter 11 Therapeutic scale stem cell-derived exosomes for COVID-19: Models---Validation, management, and strategies |
|
|
153 | (16) |
|
Francis Boniface Fernandez |
|
|
|
|
153 | (1) |
|
|
|
154 | (3) |
|
|
|
157 | (1) |
|
Stem cell population/product condition addressed outcome |
|
|
158 | (1) |
|
|
|
158 | (2) |
|
|
|
160 | (3) |
|
|
|
163 | (6) |
|
Chapter 12 Current strategies and future perspectives in COVID-19 therapy |
|
|
169 | (39) |
|
|
|
|
|
|
|
|
|
|
|
|
|
169 | (1) |
|
|
|
170 | (7) |
|
|
|
177 | (3) |
|
Current treatment strategies |
|
|
180 | (21) |
|
|
|
201 | (7) |
| Conclusion |
|
208 | (1) |
| Acknowledgments |
|
209 | (1) |
| References |
|
209 | (20) |
| Index |
|
229 | |
Dr. Chandra P. Sharma is a former Adjunct Professor, Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal University, and Hon. Emeritus Professor, College of Biomedical Engineering and Applied Sciences, Purbanchal University, Kathmandu, Nepal. Dr. Sharma is a Solid-State Physicist from IIT Delhi and received his training in biomaterials area in the University of Utah with Prof. D.J. Lyman as a graduate student and in the University of Liverpool, England, with Prof. D.F. Williams as a Post-Doctoral Research Associate. Dr. Sharma has been awarded FBSE (Fellow Biomaterials Science and Engineering) by the International Union of Societies for Biomaterials Science and Engineering (IUS-BSE) in 2008 and FBAO (Fellow Biomaterials and Artificial Organs) by the Society for Biomaterials and Artificial Organs (India) (SBAOI) in 2011 and [ 17020_LE1] shares Whitaker and National Science Foundation AwardInternational Society for Artificial Organs (ISAO) USA, invited member ACS (20152018).
[ 17020_LE1]Please check the phrase and shares Whitaker and National for clarity and amend if necessary.
Dr. Devendra K. Agrawal moved to Canada and earned PhD (Medical Sciences) in 1984 from McMaster University, Canada followed by a Postdoctoral Fellowship at the University of British Columbia, Vancouver, Canada. In 1985, he was recruited as an Asst Professor at Creighton University School of Medicine, Omaha, Nebraska where he rose to the rank of Full Professor in 1997. Dr. Agrawal also earned MBA in 2004 and MS in 2005 from Creighton University. In 2009, Dr. Agrawal founded the Center for Clinical & Translational Research at Creighton University, which later developed into an independent Department. Dr. Agrawal was the Founding Chairman of this Department. Dr. Agrawal also served as the Senior Associate Dean of Clinical & Translational Sciences at Creighton. In July 2019, he moved to California as Senior Vice President for Research and Professor of Translational Research at the Western University of Health Sciences, Pomona, CA. Dr. Finosh Thankam is an assistant professor and researcher in Tissue Engineering and Regenerative Medicine, in the Department of Translational Research, at the Western University of Health Sciences, in Pomona, CA. His undergraduate studies were in Biochemistry, before completing his post-graduate degree in Medical Biochemistry from Mahatma Gandhi University, in India. As a research fellow he was exposed to the new world of tissue engineering and regenerative medicine and published many original articles on various aspects of cardiac tissue engineering. His current research interests include investigating the pathogenesis of various musculoskeletal disorders, and cardiovascular diseases, and applying the knowledge and principles of tissue engineering to develop artificial tissue constructs to improve the care for the sufferers.
